Goldman Sachs’s Tango Therapeutics TNGX Stock Holding History
Bought
Maintained
Sold
Other funds holding TNGX
SL
Goldman Sachs's TNGX Position: Q3 2026 in Review
Goldman Sachs increased its Tango Therapeutics (TNGX) stake by 14% in Q3 2026, buying an estimated $37.3M and bringing the position to 11,412,008 shares worth $285M. The position accounts for 0.02% of the portfolio, ranked #570.
Goldman Sachs first reported a position in TNGX in Q4 2021 and has held it in 20 quarters since. The position peaked at $312M in Q2 2026. 257 funds tracked by Wall St. Rank hold TNGX as of Q3 2026.
- Goldman Sachs held 11,412,008 shares of Tango Therapeutics worth $285M as of Q3 2026.
- Goldman Sachs bought 1,431,388 Tango Therapeutics shares in Q3 2026, an estimated $37.3M.
- Tango Therapeutics made up 0.02% of Goldman Sachs's portfolio in Q3 2026, its #570 holding.
- Goldman Sachs first reported a position in Tango Therapeutics in Q4 2021 and has held it in 20 quarters since.
- Goldman Sachs's Tango Therapeutics position peaked at $312M in Q2 2026.
- 257 funds tracked by Wall St. Rank held Tango Therapeutics as of Q3 2026.
Based on Goldman Sachs's 13F filing for Q3 2026, filed 16 Nov 2026.